JP2019529520A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529520A5 JP2019529520A5 JP2019518506A JP2019518506A JP2019529520A5 JP 2019529520 A5 JP2019529520 A5 JP 2019529520A5 JP 2019518506 A JP2019518506 A JP 2019518506A JP 2019518506 A JP2019518506 A JP 2019518506A JP 2019529520 A5 JP2019529520 A5 JP 2019529520A5
- Authority
- JP
- Japan
- Prior art keywords
- biliary tract
- composition according
- composition
- tract cancer
- albumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 43
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 35
- 201000009036 biliary tract cancer Diseases 0.000 claims description 33
- 239000002105 nanoparticle Substances 0.000 claims description 22
- 102000009027 Albumins Human genes 0.000 claims description 18
- 108010088751 Albumins Proteins 0.000 claims description 18
- 229940123237 Taxane Drugs 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 10
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 10
- 206010004593 Bile duct cancer Diseases 0.000 claims description 8
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 8
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 4
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 4
- 238000009098 adjuvant therapy Methods 0.000 claims description 4
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 4
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 238000001361 intraarterial administration Methods 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 210000003445 biliary tract Anatomy 0.000 claims description 2
- 238000005336 cracking Methods 0.000 claims description 2
- 201000009777 distal biliary tract carcinoma Diseases 0.000 claims description 2
- 210000002767 hepatic artery Anatomy 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 208000014899 intrahepatic bile duct cancer Diseases 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 230000000683 nonmetastatic effect Effects 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 208000000649 small cell carcinoma Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 description 23
- 201000011510 cancer Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662405706P | 2016-10-07 | 2016-10-07 | |
| US62/405,706 | 2016-10-07 | ||
| PCT/US2017/055559 WO2018067943A1 (en) | 2016-10-07 | 2017-10-06 | Methods of treating biliary tract cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019529520A JP2019529520A (ja) | 2019-10-17 |
| JP2019529520A5 true JP2019529520A5 (Direct) | 2020-11-12 |
Family
ID=61831977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518506A Pending JP2019529520A (ja) | 2016-10-07 | 2017-10-06 | 胆道がんを処置する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200129469A1 (Direct) |
| EP (1) | EP3522887A4 (Direct) |
| JP (1) | JP2019529520A (Direct) |
| KR (1) | KR20190066033A (Direct) |
| AU (1) | AU2017340913A1 (Direct) |
| BR (1) | BR112019006329A2 (Direct) |
| CA (1) | CA3039582A1 (Direct) |
| MX (1) | MX2019003694A (Direct) |
| WO (1) | WO2018067943A1 (Direct) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| HUE070408T2 (hu) | 2015-06-29 | 2025-06-28 | Abraxis Bioscience Llc | Szirolimuszt és albumint tartalmazó nanorészecskék epitelioid sejtes tumorok kezelésében történõ alkalmazásra |
| AU2019239953B2 (en) | 2018-03-20 | 2025-01-02 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| KR20220106758A (ko) | 2019-10-28 | 2022-07-29 | 아브락시스 바이오사이언스, 엘엘씨 | 알부민 및 라파마이신의 제약 조성물 |
| US20230414783A1 (en) * | 2020-12-22 | 2023-12-28 | Ambys Medicines, Inc. | Biliary Delivery Methods, Compositions and Kits for Use Therein |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2580135T3 (es) * | 2010-03-26 | 2016-08-19 | Abraxis Bioscience, Llc | Métodos de tratamiento de carcinoma hepatocelular |
| RU2016103126A (ru) * | 2010-06-07 | 2018-11-22 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы комбинированной терапии для лечения пролиферативных заболеваний |
| WO2012151562A1 (en) * | 2011-05-04 | 2012-11-08 | Intellikine, Llc | Combination pharmaceutical compositions and uses thereof |
| US20140199404A1 (en) * | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
| US20140199405A1 (en) * | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| AU2015330731B2 (en) * | 2014-10-10 | 2020-07-09 | Idera Pharmaceuticals, Inc. | Treatment of cancer using TLR9 agonist with checkpoint inhibitors |
-
2017
- 2017-10-06 EP EP17859266.3A patent/EP3522887A4/en not_active Withdrawn
- 2017-10-06 MX MX2019003694A patent/MX2019003694A/es unknown
- 2017-10-06 JP JP2019518506A patent/JP2019529520A/ja active Pending
- 2017-10-06 US US16/338,900 patent/US20200129469A1/en not_active Abandoned
- 2017-10-06 BR BR112019006329A patent/BR112019006329A2/pt not_active Application Discontinuation
- 2017-10-06 KR KR1020197012517A patent/KR20190066033A/ko not_active Ceased
- 2017-10-06 AU AU2017340913A patent/AU2017340913A1/en not_active Abandoned
- 2017-10-06 WO PCT/US2017/055559 patent/WO2018067943A1/en not_active Ceased
- 2017-10-06 CA CA3039582A patent/CA3039582A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019529520A5 (Direct) | ||
| JP2013523656A5 (Direct) | ||
| JP2016513097A5 (Direct) | ||
| JP2013503174A5 (Direct) | ||
| Rowinsky et al. | Paclitaxel (taxol) | |
| Simon et al. | Progress in the therapy of small cell lung cancer | |
| JP2016513075A5 (Direct) | ||
| JP2013527233A5 (Direct) | ||
| JP2010509331A5 (Direct) | ||
| Markman et al. | Paclitaxel in cancer therapy | |
| RU2012156275A (ru) | Способ и лечение рака поджелудочной железы | |
| JP2020012005A (ja) | 治療薬の組み合わせおよび投与の様式ならびに併用療法 | |
| RU2009121568A (ru) | Комбинации и способы введения терапевтических агентов и комбинированная терапия | |
| HRP20160609T1 (hr) | Postupci liječenja hepatocelularnog karcinoma | |
| RU2017104909A (ru) | Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства | |
| JP2019521180A5 (Direct) | ||
| HRP20160551T1 (hr) | Kombinirana terapija s pripravcima nanočestica taksana i hedgehog inhibitora | |
| JP2010529025A5 (Direct) | ||
| JP2016506908A5 (Direct) | ||
| JP2007526455A5 (Direct) | ||
| JP2010523696A5 (Direct) | ||
| JP2020523354A5 (Direct) | ||
| JP2016515586A5 (Direct) | ||
| JP2017527582A5 (Direct) | ||
| JP2019506392A5 (Direct) |